Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

387 Views

150. HIV: Treatment: Friday, 12:15 - 1:30 p.m.

Poster Session: HIV: Treatment

(1608) Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA^® Cohort

Friday, October 13, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Michael Sension, MD (he/him/his)

Medical Director
CAN Community Health
Fort Lauderdale, Florida, United States

Ricky K. Hsu, MD (he/him/his)

National Medical Director of Clinical Standards, Policy, & Education\ Associate Professor of Medicine
AIDS Healthcare Foundation/ NYU School of Medicine
New York, NY, United States
Jennifer S. Fusco, BS

Chief Science Officer
Epividian, Inc.
Durham, North Carolina, United States
LB

Laurence Brunet, PhD

Director of Epidemiology
Epividian, Inc.
Durham, North Carolina, United States
QC

Quateka Cochran, Masters of Nursing

Regional Nursing Director
Aids Healthcare Foundation
Miami Beach, Florida, United States
GS

Gayathri Sridhar, MBBS, MPH, PhD

Director
ViiV Healthcare
Fairfax, Virginia, United States
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States
Jv

Jean A. van Wyk, MBChB, MFPM

Medical Director
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
MW

Michael B. Wohlfeiler, JD, MD, AAHIVS

Chief Medical Officer
AIDS Healthcare Foundation
Miami Beach, Florida, United States
GF

Gregory P. Fusco, MD, MPH

Chief Executive Officer & Chief Medical Officer
Epividian, Inc.
Durham, North Carolina, United States